MarketOptimizer.

org adds report Acute Coronary Syndrome US Drug Forecast and Market Analysis to
2023 to its store.

The total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales
(40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a
CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of
which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn).
The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is
flush with well-established standard-of-care therapies, many of which are generic. Therefore, the
pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan
biochemical pathways. The ACS market will be driven by an aging population with a preponderance of
lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as
diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is
expected to significantly and fundamentally alter the ACS market, both medically and financially.

Complete report available @ http://www.marketoptimizer.org/acute-coronary-syndrome-us-drug-
forecast-and-market-analysis-to-2023.html .

Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in
sales for every class and brand of drug, by a very large margin. The statin share can predominantly be
attributed to sales volume as most statins, with the exception of Crestor, are available as inexpensive
generics. Contrarily, the large market share from the ARBs is due to the relatively high cost of therapy
and the presence of branded options still on the market.

Scope

Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the US ACS
market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for ACS
Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug
performance
Obtain sales forecast for drugs from 2013-2023 in the US

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-
buying?rname=10327 .
(This is a premium report priced at US$6995 for a single user PDF.)

List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 19
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 20
Table 3: Symptoms of Acute Coronary Syndrome 25
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 30
Table 5: Most Prescribed Drugs for ACS by Class in the US, 2014 30
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 37
Table 7: Commonly Used tPAs 41
Table 8: Product Profile Tissue Plasminogen Activator (tPA) 41
Table 9: Fibrinolytics?SWOT Analysis, 2014 43
Table 10: Product Profile Plavix (clopidogrel) 45
Table 11: Clopidogrel SWOT Analysis, 2014 47
Table 12: Product Profile Brilinta (ticagrelor) 49
Table 13: Brilinta (ticagrelor) SWOT Analysis, 2014 50
Table 14: Product Profile Effient (prasugrel) 53
Table 15: Effient (prasugrel) SWOT Analysis, 2014 55
Table 16: Product Profile Integrilin (eptifibatide) 56
Table 17: Integrilin (eptifibatide) SWOT Analysis, 2014 57
Table 18: Product Profile Warfarin 60
Table 19: Warfarin SWOT Analysis, 2014 62
Table 20: Product Profile Angiomax 63
Table 21: Angiomax (bivalirudin) SWOT Analysis, 2014 64
Table 22: Product Profile Arixtra (fondaparinux) 66
Table 23: Arixtra (fondaparinux sodium) SWOT Analysis, 2014 69
Table 24: Product Profile Lipitor 71
Table 25: Lipitor (atorvastatin) SWOT Analysis, 2014 73
Table 26: Product Profile Crestor (rosuvastatin) 75
Table 27: Crestor (rosuvastatin) SWOT Analysis, 2014 77
Table 28: Product Profile Zocor (simvastatin) 78
Table 29: Zocor (simvastatin) SWOT Analysis, 2014 80
Table 30: Commonly Used Beta Blockers 81
Table 31: Product Profile Beta Blockers 82
Table 32: Beta Blockers SWOT Analysis, 2014 83
Table 33: Product Profile Tekturna (aliskiren) 85
Table 34: Tekturna (aliskiren) SWOT Analysis, 2014 87
Table 35: Commonly Used ACE Inhibitors 88
Table 36: Product Profile ACE Inhibitors 88
Table 37: ACE Inhibitor?SWOT Analysis, 2014 90
Table 38: Commonly Used ARBs 91
Table 39: Product Profile Angiotensin Receptor Blockers (ARBs) 91
Table 40: ARB SWOT Analysis, 2014 93
Table 41: Product Profile Mineralocorticoid Receptor Antagonists (MRAs) 94
Table 42: MRA SWOT Analysis, 2014 96
Table 43: Unmet Need and Opportunity in Acute Coronary Syndrome 97
Table 44: Acute Coronary Syndrome Clinical Trials by Phase and Status, 2014 113
Table 45: Acute Coronary Syndrome Late-Stage Pipeline, 2014 116
Table 46: Comparison of Therapeutic Classes in Development for ACS, 2014 117
Table 47: Product Profile Xarelto (rivaroxaban) 121
Table 48: Xarelto (rivaroxaban) SWOT Analysis, 2014 125
Table 49: Product Profile Cangrelor 127
Table 50: Cangrelor SWOT Analysis, 2014 132
Table 51: Product Profile Zontivity (vorapaxar) 134
Table 52: Vorapaxar SWOT Analysis, 2014 138
Table 53: Product Profile Alirocumab (RGN727) 140
Table 54: Alirocumab SWOT Analysis, 2014 145
Table 55: Product Profile Evolocumab (AMG 145) 148
Table 56: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 Q1 2014 149
Table 57: Evolocumab SWOT Analysis, 2013 154
Table 58: Product Profile Bococizumab (PF-04950615) 156
Table 59: Bococizumab (PF-04950615) SWOT Analysis, 2014 158
Table 60: Product Profile Anacetrapib 161
Table 61: Anacetrapib SWOT Analysis, 2014 165
Table 62: Product Profile Evacetrapib 167
Table 63: Evacetrapib SWOT Analysis, 2013 169
Table 64: Product Profile Darapladib 172
Table 65: Darapladib SWOT Analysis, 2014 175
Table 66: Sales Forecasts ($m) for ACS in US, 20132023 177
Table 67: Key Events Impacting Sales for Acute Coronary Syndrome in the US, 2014 180
Table 68: Acute Coronary Syndrome Market Drivers and Barriers, 2014 181
Table 69: Acute Coronary Syndrome Market Drivers and Barriers in the US, 2014 186
Table 70: Key Launch Dates 210
Table 71: Key Patent Expiries 210
Table 72: Price Sources and Calculations, in US 211
Table 73: Physicians Surveyed, By Country 223

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10327 .

About Us:
MarketOptimizer.org is your single source for all market research needs. Our database includes
450,000+ market research reports from over 95 leading global publishers & in-depth market research
studies of over 5000 micro markets. We offer you customization options on reports by & custom reports
through MarketsandMarkets.com. With comprehensive information about the publishers and the
industries for which they publish market research reports, we help you in your purchase decision by
mapping your information needs with our huge collection of reports.